CN Patent

CN113164486A — 用于治疗膀胱过度活动症症状的维贝格龙

Assigned to Sumitomo Pharmaceutical Suzhou Co Ltd · Expires 2021-07-23 · 5y expired

What this patent protects

本公开内容涉及一种治疗患有良性前列腺增生的男性中的膀胱过度活动症症状的方法，该方法包括每天向有相应需要的受试者口服施用从约60mg至约90mg(例如，约75mg)的量的维贝格龙。

USPTO Abstract

本公开内容涉及一种治疗患有良性前列腺增生的男性中的膀胱过度活动症症状的方法，该方法包括每天向有相应需要的受试者口服施用从约60mg至约90mg(例如，约75mg)的量的维贝格龙。

Drugs covered by this patent

Patent Metadata

Patent number
CN113164486A
Jurisdiction
CN
Classification
—
Expires
2021-07-23
Drug substance claim
No
Drug product claim
No
Assignee
Sumitomo Pharmaceutical Suzhou Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.